These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16862529)

  • 21. Type 1 von Willebrand disease: application of emerging data to clinical practice.
    Collins PW; Cumming AM; Goodeve AC; Lillicrap D
    Haemophilia; 2008 Jul; 14(4):685-96. PubMed ID: 18510569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.
    Franchini M; Montagnana M; Lippi G
    Int J Lab Hematol; 2008 Apr; 30(2):91-4. PubMed ID: 18333841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inherited and de novo von Willebrand disease 'Vicenza' in UK families with the R1205H mutation: diagnostic pitfalls and new insights.
    Lester WA; Guilliatt AM; Surdhar GK; Enayat SM; Wilde JT; Willoughby S; Grundy P; Cumming AM; Collins PW; Hill FG
    Br J Haematol; 2006 Oct; 135(1):91-6. PubMed ID: 16925796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of von Willebrand disease subtypes: implications for treatment.
    Budde U
    Haemophilia; 2008 Nov; 14 Suppl 5():27-38. PubMed ID: 18786008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients.
    Gupta PK; Saxena R; Adamtziki E; Budde U; Oyen F; Obser T; Schneppenheim R
    Blood Cells Mol Dis; 2008; 41(2):219-22. PubMed ID: 18485763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of von Willebrand disease.
    Cox Gill J
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1277-99, viii. PubMed ID: 15511616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Von Willebrand disease in childhood.
    Schneppenheim R; Thomas KB; Sutor AH
    Semin Thromb Hemost; 1995; 21(3):261-75. PubMed ID: 8588154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
    Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
    Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Getting at the variable expressivity of von Willebrand disease.
    Levy G; Ginsburg D
    Thromb Haemost; 2001 Jul; 86(1):144-8. PubMed ID: 11487001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. von Willebrand disease update: diagnostic and treatment dilemmas.
    Bolton-Maggs PH; Lillicrap D; Goudemand J; Berntorp E
    Haemophilia; 2008 Jul; 14 Suppl 3():56-61. PubMed ID: 18510523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
    Jacquemin M
    Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.
    Favaloro EJ
    Semin Thromb Hemost; 2007 Nov; 33(8):727-44. PubMed ID: 18175279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autosomal dominant von Willebrand disease type 2M.
    Hermans C; Batlle J
    Acta Haematol; 2009; 121(2-3):139-44. PubMed ID: 19506360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.